{"id":"hydroxychloroquine-pre-exposure-prophylaxis","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Dizziness"},{"rate":"<1","effect":"Retinopathy (with long-term use)"},{"rate":"<1","effect":"Cardiomyopathy (rare, with prolonged use)"}]},"_chembl":{"chemblId":"CHEMBL1535","moleculeType":"Small molecule","molecularWeight":"335.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydroxychloroquine is a quinoline antimalarial and immunomodulatory agent that increases endosomal pH, inhibits toll-like receptor signaling, and reduces production of pro-inflammatory cytokines including TNF-α and IL-6. In pre-exposure prophylaxis, it is hypothesized to prime innate immune responses and reduce viral replication capacity at mucosal surfaces, thereby preventing initial infection or reducing severity of infection upon exposure.","oneSentence":"Hydroxychloroquine modulates immune responses and reduces inflammatory cytokine production to prevent infection establishment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:55:14.042Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pre-exposure prophylaxis for infectious disease (specific pathogen under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT04331834","phase":"PHASE3","title":"Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic","status":"COMPLETED","sponsor":"Barcelona Institute for Global Health","startDate":"2020-04-03","conditions":"COVID-19","enrollment":275},{"nctId":"NCT04354870","phase":"PHASE2","title":"COVID-19 PrEP HCW HCQ Study","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-04-03","conditions":"COVID-19","enrollment":130},{"nctId":"NCT04334928","phase":"PHASE3","title":"Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel","status":"COMPLETED","sponsor":"Plan Nacional sobre el Sida (PNS)","startDate":"2020-04-15","conditions":"Coronavirus Infection","enrollment":1002},{"nctId":"NCT04328467","phase":"PHASE3","title":"Pre-exposure Prophylaxis for SARS-Coronavirus-2","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2020-04-06","conditions":"COVID-19, Corona Virus Infection, ARDS","enrollment":1483},{"nctId":"NCT04374942","phase":"PHASE3","title":"Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?","status":"TERMINATED","sponsor":"Megan Landes","startDate":"2020-04-30","conditions":"Pre-Exposure Prophylaxis, Coronavirus, SARS-CoV 2","enrollment":13},{"nctId":"NCT04384458","phase":"NA","title":"Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis","status":"UNKNOWN","sponsor":"Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara","startDate":"2020-07-20","conditions":"Coronavirus Infections","enrollment":400},{"nctId":"NCT04359537","phase":"PHASE2","title":"Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19","status":"UNKNOWN","sponsor":"Shaheed Zulfiqar Ali Bhutto Medical University","startDate":"2020-05-01","conditions":"COVID 19","enrollment":200},{"nctId":"NCT04352946","phase":"PHASE3","title":"HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial","status":"UNKNOWN","sponsor":"GeoSentinel Foundation","startDate":"2020-04-24","conditions":"Prophylaxis, COVID-19, Health Care Worker","enrollment":374}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":41,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hydroxychloroquine PreP","HCQ PreP"],"phase":"phase_3","status":"active","brandName":"Hydroxychloroquine Pre-Exposure Prophylaxis","genericName":"Hydroxychloroquine Pre-Exposure Prophylaxis","companyName":"GeoSentinel Foundation","companyId":"geosentinel-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydroxychloroquine modulates immune responses and reduces inflammatory cytokine production to prevent infection establishment. Used for Pre-exposure prophylaxis for infectious disease (specific pathogen under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}